Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRAGE trial of regorafenib for recurrent meningioma
2024-510954-28-01Phase 2Authorised
- Sponsor
- Istituto Oncologico Veneto
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regorafenib in meningioma (2 arms), sponsored by Istituto Oncologico Veneto. Primary endpoint: Progression-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
regorafenib
03
Conditions
meningioma
Beyond the preview
Go deeper on 2024-510954-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510954-28-01.